Monoethylglycinexylidide (hydrochloride)

Monoethylglycinexylidide (MEGX) hydrochloride is a metabolite of Lidocain (HY-B0185) via oxidative N-deethylation of Lignocaine by liver cytochrome P-450 enzymes in the liver. Monoethylglycinexylidide has proven to be a highly sensitive indicator of hepatic dysfunction, especially in the field of liver transplantation[1][2].

Product Specifications

CAS Number

[7729-94-4]

Product Name Alternative

MEGX (hydrochloride) ; Norlidocaine (hydrochloride)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Drug Metabolite

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/monoethylglycinexylidide-hydrochloride.html

Purity

98.82

Solubility

10 mM in DMSO|DMSO : ≥ 5mg/mL

Smiles

CCNCC(NC1=C(C)C=CC=C1C)=O.Cl

Molecular Formula

C12H19ClN2O

Molecular Weight

242.75

Precautions

H302, H315, H319, H335

References & Citations

[1]Huang YS, et al. Measuring lidocaine metabolite--monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis. J Hepatol. 1993 Aug;19 (1) :140-7.|[2]Esen F, et al. Monoethylglycinexylidide (MEGX) as an early predictor of liver dysfunction in severe sepsis. Critical Care, 1997, 1 (Suppl 1) :P083.